Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.49 |
| ▸ | CCNK | O75909 | 9/20 | 0.49 |
| ▸ | CDK12 | Q9NYV4 | 9/20 | 0.49 |
| ▸ | CCNT1 | O60563 | 8/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.49 |
| ▸ | CDK9 | P50750 | 8/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.49 |
| ▸ | MAPK9 | P45984 | 8/20 | 0.49 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.49 |
| ▸ | JUN | P05412 | 7/20 | 0.49 |
| ▸ | CDK7 | P50613 | 6/20 | 0.46 |
| ▸ | CCNH | P51946 | 6/20 | 0.46 |
| ▸ | MNAT1 | P51948 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25597463 | 0.90 | CCNK (0.63) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL30204068 | 0.90 | CCNK (0.63) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL24588759 | 0.90 | CCNK (0.63) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL31006821 | 0.87 | MAPK8 (0.54) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL30204073 | 0.86 | CDK7 (0.65) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL25600682 | 0.86 | CDK7 (0.65) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL25600689 | 0.86 | CDK7 (0.65) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL30204515 | 0.83 | CDK2 (0.49) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL25598586 | 0.83 | CDK2 (0.49) | CDK2CCNKCDK12CCNT1CCNE1 | |
| SCHEMBL25593182 | 0.82 | CDK2 (0.63) | CDK2CCNKCDK12CCNT1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-4295852-A2 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3484871-B1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | SYROS PHARMACEUTICALS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360165-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 10/4885CCNK 11/4885CDK12 28/4885 |
| US-20230062491-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | CDK2 10/4885CCNK 11/4885CDK12 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.